Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma

The BTK inhibitor ibrutinib has demonstrated a remarkable therapeutic effect in mantle cell lymphoma (MCL). However, approximately one-third of patients do not respond to the drug initially. To identify the mechanisms underlying primary ibrutinib resistance in MCL, we analyzed the transcriptome chan...

全面介紹

Na minha lista:
書目詳細資料
發表在:Blood Adv
Main Authors: Lee, Jimmy, Zhang, Liang Leo, Wu, Wenjun, Guo, Hui, Li, Yan, Sukhanova, Madina, Venkataraman, Girish, Zhang, Hui, Alikhan, Mir, Lu, Pin, Guo, Ailin, Galanina, Natalie, Andrade, Jorge, Wang, Michael L., Wang, Y. Lynn
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2018
主題:
Lymphoid Neoplasia
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6113611/
https://ncbi.nlm.nih.gov/pubmed/30115641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018016048
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍